GeneDx Holdings Corp. (NASDAQ: WGS), a leading provider of cell-free DNA testing solutions, saw its stock surge by 5.47% in the pre-market trading session on Wednesday. This surge followed the company's announcement of its innovation roadmap and advancements in molecular residual disease (MRD) testing and early cancer detection products.
According to the announcement, GeneDx is introducing a new version of its Signatera assay, designed on the whole genome sequence (WGS) of a patient's tumor. This genome-based assay is expected to enhance the company's MRD testing capabilities, building upon the success of its exome-based Signatera assay.
Additionally, GeneDx unveiled a new tissue-free MRD capability, leveraging its expertise in methylation-based technologies. The first launch in this line is expected in mid-2025 for colorectal cancer, with more tumor indications to follow. The company also shared promising early performance data for its early cancer detection (ECD) assay, demonstrating high detection rates for stage 1 colorectal cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.